Analysts Offer Insights on Healthcare Companies: Genfit SA (NASDAQ: GNFT), Aquestive Therapeutics Inc (NASDAQ: AQST) and Aslan Pharmaceuticals Ltd (NASDAQ: ASLN)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genfit SA (GNFTResearch Report), Aquestive Therapeutics Inc (AQSTResearch Report) and Aslan Pharmaceuticals Ltd (ASLNResearch Report) with bullish sentiments.

Genfit SA (GNFT)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Genfit SA, with a price target of $72.00. The company’s shares closed last Monday at $17.41.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.2% and a 34.2% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings Inc, Madrigal Pharmaceuticals Inc, and Arcturus Therapeutics Ltd.

Genfit SA has an analyst consensus of Moderate Buy, with a price target consensus of $62.00.

See today’s analyst top recommended stocks >>

Aquestive Therapeutics Inc (AQST)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aquestive Therapeutics Inc today and set a price target of $12.00. The company’s shares closed last Monday at $3.18, close to its 52-week low of $2.95.

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -16.6% and a 22.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Turning Point Therapeutics Inc.

Aquestive Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $18.50, which is a 492.9% upside from current levels. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $34.00 price target.

Aslan Pharmaceuticals Ltd (ASLN)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Aslan Pharmaceuticals Ltd today and set a price target of $9.00. The company’s shares closed last Monday at $1.73, close to its 52-week low of $1.50.

According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -20.7% and a 27.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.

Aslan Pharmaceuticals Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.